NICE draft guidance extends recommendations on Alzheimer's drugs
In its latest draft guidance, NICE has confirmed that it is extending previous recommendations for the use of three drugs - Donepezil (Aricept, Eisai/Pfizer), galantamine (Reminyl, Shire) and rivastigmine (Exelon, Novartis) - to include mild, as well as moderate Alzheimer's disease. It also recommends the use of memantine (Ebixa, Lundbeck) for severe disease and for some patients with moderate disease.
Chief Executive, Sir Andrew Dillon said: “We are pleased to now be able to recommend these three drugs for both mild and moderate Alzheimer's disease and another for moderate or severe Alzheimer's, extending recommendations made in 2007.
"Since 2007 clinical trials have continued to show the positive effects of these drugs and, in the case of memantine, have reduced the uncertainty about its clinical effectiveness. In addition, we now have more information about the costs of living with and treating this very distressing disease, as it progresses through its mild, moderate and severe stages.”
The draft guidance is now with consultees, who have the opportunity to appeal against the proposedrecommendations. Final guidance is expected to be published in March 2011. This new appraisal reviews recommendations made in Technology Appraisal 111 published in September 2007. Until NICE issues final guidance, the recommendations made in 2007 remain in place.
Notes to Editors
About the appraisal
1. View the Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (review) for further information
2. NICE published its first draft guidance on this appraisal in October 2010. Following consultation on that draft, the recommendations remain unchanged.
3. Donepezil (Aricept, Eisai/Pfizer), galantamine (Reminyl, Shire) and rivastigmine (Exelon, Novartis) are recommended within their licensed indications for mild to moderate Alzheimer's disease as options for managing Alzheimer's disease. Memantine (Ebixa, Lundbeck) is recommended as an option in managing Alzheimer's disease for people with moderate Alzheimer's disease who are intolerant of or have a contraindication to AChE inhibitors, or people with severe Alzheimer's disease.
4. The National Institute for Health and Care Excellence (NICE) is the independent organisation responsible for providing national guidance and standards on the promotion of good health and the prevention and treatment of ill health
5. NICE produces guidance in three areas of health:
- public health - guidance on the promotion of good health and the prevention of ill health for those working in the NHS, local authorities and the wider public and voluntary sector
- health technologies - guidance on the use of new and existing medicines, treatments, medical technologies (including devices and diagnostics) and procedures within the NHS
- clinical practice - guidance on the appropriate treatment and care of people with specific diseases and conditions within the NHS.
6. NICE produces standards for patient care:
- quality standards - these reflect the very best in high quality patient care, to help healthcare practitioners and commissioners of care deliver excellent services
- Quality and Outcomes Framework - NICE develops the clinical and health improvement indicators in the QOF, the Department of Health scheme which rewards GPs for how well they care for patients
7. NICE provides advice and support on putting NICE guidance and standards into practice through its implementation programme, and it collates and accredits high quality health guidance, research and information to help health professionals deliver the best patient care through NHS Evidence.
This page was last updated: 18 January 2011